

# Herpes Labialis (Oral Herpes) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/HABF46C51520EN.html>

Date: October 2022

Pages: 42

Price: US\$ 2,000.00 (Single User License)

ID: HABF46C51520EN

## Abstracts

Herpes Labialis (Oral Herpes) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Herpes Labialis (Oral Herpes) - Drugs In Development, 2022, provides an overview of the Herpes Labialis (Oral Herpes) (Infectious Disease) pipeline landscape.

Oral herpes is an infection of the lips, mouth, or gums due to the herpes simplex virus. Oral herpes is also called herpes labialis. Symptoms include sore throat, fever, swollen glands and painful swallowing. Treatment includes antiviral medications.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Herpes Labialis (Oral Herpes) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Herpes Labialis (Oral Herpes) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Herpes Labialis (Oral Herpes) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Herpes Labialis (Oral Herpes) and

features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 3, 5 and 1 respectively.

Herpes Labialis (Oral Herpes) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Herpes Labialis (Oral Herpes) (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Herpes Labialis (Oral Herpes) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Herpes Labialis (Oral Herpes) (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Herpes Labialis (Oral Herpes) (Infectious Disease)

therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Herpes Labialis (Oral Herpes) (Infectious Disease)

## REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Herpes Labialis (Oral Herpes) (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Herpes Labialis (Oral Herpes) (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



## Contents

Introduction

Global Markets Direct Report Coverage

Herpes Labialis (Oral Herpes) - Overview

Herpes Labialis (Oral Herpes) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Herpes Labialis (Oral Herpes) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Herpes Labialis (Oral Herpes) - Companies Involved in Therapeutics Development

AiCuris Anti-infective Cures AG

Astellas Pharma Inc

Brandenburg Antiinfektiva GmbH

Dobecure SL

Heidelberg Immunotherapeutics GmbH

Jupiter Wellness Inc

NanoViricides Inc

Rational Vaccines Inc

Shulov Innovative Science Ltd

Vironova Medical AB

Herpes Labialis (Oral Herpes) - Drug Profiles

amenamevir - Drug Profile

Product Description

Mechanism Of Action

Aspidasept - Drug Profile

Product Description

Mechanism Of Action

B-220 - Drug Profile

Product Description

Mechanism Of Action

Cold Sores - Drug Profile

Product Description

Mechanism Of Action

ethamsylate - Drug Profile

Product Description  
Mechanism Of Action  
HDIT-101 - Drug Profile  
Product Description  
Mechanism Of Action  
JW-100 - Drug Profile  
Product Description  
Mechanism Of Action  
JW-400 - Drug Profile  
Product Description  
Mechanism Of Action  
NVHHV-101 - Drug Profile  
Product Description  
Mechanism Of Action  
pritelivir - Drug Profile  
Product Description  
Mechanism Of Action  
RVX-101HSV1 - Drug Profile  
Product Description  
Mechanism Of Action  
ZEP-3 - Drug Profile  
Product Description  
Mechanism Of Action  
ZEP-4 - Drug Profile  
Product Description  
Mechanism Of Action  
Herpes Labialis (Oral Herpes) - Dormant Projects  
Herpes Labialis (Oral Herpes) - Discontinued Products  
Herpes Labialis (Oral Herpes) - Product Development Milestones  
Featured News & Press Releases  
Nov 17, 2020: Jupiter Wellness' JW-100 enters clinical trial for the treatment of Herpes  
Aug 23, 2017: AiCuris Announces Final Patient Treated in Clinical Phase 2 Trial with Topical Pritelivir for the Treatment of recurrent Labial Herpes  
Dec 01, 2016: AiCuris Announces Start of LipP 1: First Subject Enrolled in the Clinical Phase 2 Trial with Topical Pritelivir for the Treatment of recurrent Labial Herpes  
Nov 05, 2010: AiCuris To Present Preclinical And Phase I Data Of Anti-HSV Drug AIC316 At Antivirals Congress  
Appendix  
Methodology

[Coverage](#)  
[Secondary Research](#)  
[Primary Research](#)  
[Expert Panel Validation](#)  
[Contact Us](#)  
[Disclaimer](#)

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Herpes Labialis (Oral Herpes), 2022  
Number of Products under Development by Companies, 2022  
Products under Development by Companies, 2022  
Number of Products by Stage and Target, 2022  
Number of Products by Stage and Mechanism of Action, 2022  
Number of Products by Stage and Route of Administration, 2022  
Number of Products by Stage and Molecule Type, 2022  
Herpes Labialis (Oral Herpes) - Pipeline by AiCuris Anti-infective Cures AG, 2022  
Herpes Labialis (Oral Herpes) - Pipeline by Astellas Pharma Inc, 2022  
Herpes Labialis (Oral Herpes) - Pipeline by Brandenburg Antiinfektiva GmbH, 2022  
Herpes Labialis (Oral Herpes) - Pipeline by Dobecure SL, 2022  
Herpes Labialis (Oral Herpes) - Pipeline by Heidelberg Immunotherapeutics GmbH, 2022  
Herpes Labialis (Oral Herpes) - Pipeline by Jupiter Wellness Inc, 2022  
Herpes Labialis (Oral Herpes) - Pipeline by NanoViricides Inc, 2022  
Herpes Labialis (Oral Herpes) - Pipeline by Rational Vaccines Inc, 2022  
Herpes Labialis (Oral Herpes) - Pipeline by Shulov Innovative Science Ltd, 2022  
Herpes Labialis (Oral Herpes) - Pipeline by Vironova Medical AB, 2022  
Herpes Labialis (Oral Herpes) - Dormant Projects, 2022  
Herpes Labialis (Oral Herpes) - Discontinued Products, 2022



## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Herpes Labialis (Oral Herpes), 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

## I would like to order

Product name: Herpes Labialis (Oral Herpes) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/HABF46C51520EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HABF46C51520EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

